1998
DOI: 10.1007/bf02303638
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic node dissections in malignant melanoma

Abstract: Therapeutic node dissections in melanoma provide an appreciable 5-year survival rate, which is further augmented by adjuvant therapy. Many series report a significant rate of local recurrence at the nodal basin following therapeutic dissection. Complete lymphadenectomy reduces the rate of local failure with its attendant morbidity.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
36
0
2

Year Published

2001
2001
2008
2008

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 49 publications
(42 citation statements)
references
References 46 publications
4
36
0
2
Order By: Relevance
“…Most authors concur that the extent of dissection should include Level I, II, and III lymph nodes, although some include Level III only when suspicious nodes are present [22][23][24]. With this approach, local recurrence is reported in 3-17% of patients (Table II) [21,[25][26][27].…”
Section: Axillary Dissection Extent Of Dissectionmentioning
confidence: 96%
See 3 more Smart Citations
“…Most authors concur that the extent of dissection should include Level I, II, and III lymph nodes, although some include Level III only when suspicious nodes are present [22][23][24]. With this approach, local recurrence is reported in 3-17% of patients (Table II) [21,[25][26][27].…”
Section: Axillary Dissection Extent Of Dissectionmentioning
confidence: 96%
“…In practice, no increase in complications was noted by Karakousis et al with this approach although there was no concurrent comparison group [26]. Preservation of the long thoracic and thoracodorsal nerve is considered routine although the intercostobrachial nerves are often resected in a therapeutic nodal dissection [22,23].…”
Section: Axillary Dissection Extent Of Dissectionmentioning
confidence: 97%
See 2 more Smart Citations
“…ELND is associated with a considerable complication rate and is no longer recommended [16]. The SLNB concept to evaluate the clinically negative regional nodal basin(s) was initially reported by Cabanas [17] for penile cancer and later described for melanoma by Morton et al in 1992 [18].…”
Section: Management Of Primary Melanoma With Clinically Negative Lympmentioning
confidence: 99%